Article
Oncology
Radka Stoyanova, Olmo Zavala-Romero, Deukwoo Kwon, Adrian L. Breto, Isaac R. Xu, Ahmad Algohary, Mohammad Alhusseini, Sandra M. Gaston, Patricia Castillo, Oleksandr N. Kryvenko, Elai Davicioni, Bruno Nahar, Benjamin Spieler, Matthew C. Abramowitz, Alan Dal Pra, Dipen J. Parekh, Sanoj Punnen, Alan Pollack
Summary: In this study, clinical- and radiomics-based models were built to predict lesions/patients at low risk using a combined clinical-genomic classification system. Radiomic features improved the performance in all cases.
Article
Multidisciplinary Sciences
Christoph Dumke, Timo Gemoll, Martina Oberlaender, Sandra Freitag-Wolf, Christoph Thorns, Axel Glaessgen, Rinse Klooster, Silvere M. van der Maarel, Jerker Widengren, Christian Doehn, Gert Auer, Jens K. Habermann
Summary: Current prostate cancer risk classifications based on clinicopathological parameters may lead to uncertainties in prognostication. Studying the predictive value of specific proteins in relation to tumor heterogeneity and genomic instability can improve individual risk stratification accuracy. Factors such as SATB1, SPIN1, and genomic instability play significant roles in identifying patient risk and overall survival outcomes.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Christopher Gaffney, Deli Liu, Victoria Cooley, Xiayoue Ma, Cynthia Angulo, Brian Robinson, Francesca Khani, Peter Cai, Simpa Salami, Srinivas Nallandhighal, Jonathan Shoag, Christopher Barbieri
Summary: The study shows that prostate tumor size is associated with aggressive tumor biology and genomic risk, independently correlated with gene expression and genomic risk markers. Tumors of different sizes exhibit distinct gene expression patterns and enrichment of different gene sets, suggesting the potential significance of tumor size in future assessment of cancer aggressiveness.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Genetics & Heredity
Jodell E. Linder, Aimee Allworth, Sarah T. Bland, Pedro J. Caraballo, Rex L. Chisholm, Ellen Wright Clayton, David R. Crosslin, Ozan Dikilitas, Alanna DiVietro, Edward D. Esplin, Sophie Forman, Robert R. Freimuth, Adam S. Gordon, Richard Green, Maegan Harden, Ingrid A. Holm, Gail P. Jarvik, Elizabeth W. Karlson, Sofia Labrecque, Niall J. Lennon, Nita A. Limdi, Kathleen F. Mittendorf, Shawn N. Murphy, Lori Orlando, Cynthia A. Prows, Luke Rasmussen, Laura Rasmussen-Torvik, Robb Rowley, Konrad Teodor Sawicki, Tara Schmidlen, Shannon Terek, David Veenstra, Digna R. Velez Edwards, Devin Absher, Noura S. Abul-Husn, Jorge Alsip, Hana Bangash, Mark Beasley, Jennifer E. Below, Eta S. Berner, James Booth, Wendy K. Chung, James J. Cimino, John Connolly, Patrick Davis, Beth Devine, Stephanie M. Fullerton, Candace Guiducci, Melissa L. Habrat, Heather Hain, Hakon Hakonarson, Margaret Harr, Eden Haverfield, Valentina Hernandez, Christin Hoell, Martha Horike-Pyne, George Hripcsak, Marguerite R. Irvin, Christopher Kachulis, Dean Karavite, Eimear E. Kenny, Atlas Khan, Krzysztof Kiryluk, Bruce Korf, Leah Kottyan, Iftikhar J. Kullo, Katie Larkin, Cong Liu, Edyta Malolepsza, Teri A. Manolio, Thomas May, Elizabeth M. McNally, Frank Mentch, Alexandra Miller, Sean D. Mooney, Priyanka Murali, Brenda Mutai, Naveen Muthu, Bahram Namjou, Emma F. Perez, Megan J. Puckelwartz, Tejinder Rakhra-Burris, Dan M. Roden, Elisabeth A. Rosenthal, Seyedmohammad Saadatagah, Maya Sabatello, Dan J. Schaid, Baergen Schultz, Lynn Seabolt, Gabriel Q. Shaibi, Richard R. Sharp, Brian Shirts, Maureen E. Smith, Jordan W. Smoller, Rene Sterling, Sabrina A. Suckiel, Jeritt Thayer, Hemant K. Tiwari, Susan B. Trinidad, Theresa Walunas, Wei-Qi Wei, Quinn S. Wells, Chunhua Weng, Georgia L. Wiesner, Ken Wiley, Josh F. eMERGE Consortium, Josh F. Peterson
Summary: To assess the risk of common, complex diseases, it is important to consider clinical risk factors as well as monogenic and polygenic risks, which can be reflected in family history. Returning risk information to individuals and providers can impact preventive healthcare and the use of prophylactic therapies for those at high genetic risk.
GENETICS IN MEDICINE
(2023)
Article
Oncology
Rachel M. Glicksman, Andrew Loblaw, Gerard Morton, Ewa Szumacher, Hans T. Chung, Danny Vesprini, William Chu, Stanley K. Liu, Richard Choo, Andrea Deabreu, Alexandre Mamedov, Liying Zhang, Patrick Cheung
Summary: The study demonstrates that EPNI and a simultaneous hypofractionated prostate boost combined with long-term ADT for high-risk prostate cancer resulted in acceptable 10-year biochemical control and survival with low grade >3 toxicity.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Genetics & Heredity
Meng Wang, Ishani Banik, A. Hunter Shain, Iwei Yeh, Boris C. Bastian
Summary: This study conducted a meta-analysis of sequencing data from acral and mucosal melanoma samples and identified important genetic mutations and gene amplifications, providing important clues for understanding the pathogenesis and therapeutic targets of these difficult-to-treat cancers.
Article
Health Care Sciences & Services
Gianluca Ingrosso, Emanuele Ali, Simona Marani, Simonetta Saldi, Rita Bellavita, Cynthia Aristei
Summary: This article reviewed the literature of the past 10 years and provided an overview of commercially available tissue-based biomarkers, specifically mRNA-based gene expression classifiers. Despite the published data, the systematic use of these tests in prostate cancer is currently not recommended due to insufficient evidence.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Clinical Neurology
Thomas Hielscher, Martin Sill, Philipp Sievers, Damian Stichel, Sebastian Brandner, David T. W. Jones, Andreas von Deimling, Felix Sahm, Sybren L. N. Maas
Summary: Risk prediction for meningioma tumors has traditionally relied on morphological features, but incorporating molecular features improves accuracy. This study confirms the practicality of using a newer brain tumor classifier and suggests that additional testing for certain mutations may not be necessary when calculating risk scores for individual patients.
Article
Oncology
Nishwant Swami, Yefri A. Baez, Idalid Franco, Tiffany Nguyen, Karthik Meiyappan, Minh Ton, Bhav Jain, Crystal Seldon, Kenrick Ng, Narjust Duma, Mohammed Alshalalfa, Kosj Yamoah, Paul L. Nguyen, Brandon A. Mahal, Edward Christopher Dee
Summary: This study found substantial heterogeneity in risk group and treatment for prostate cancer among Hispanic subgroups, indicating the importance of disaggregated data collection and further exploration of potential underlying mechanisms.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Ya-Sian Chang, Siang-Jyun Tu, Hong-Da Chen, Ming-Hon Hsu, Yu-Chia Chen, Dy-San Chao, Chin-Chun Chung, Yu-Pao Chou, Chieh-Min Chang, Ya-Ting Lee, Ju-Chen Yen, Long-Bin Jeng, Jan-Gowth Chang
Summary: This study investigated the impact of genomic alterations and transcriptomic changes on clinical and molecular characteristics of Taiwanese hepatocellular carcinoma (HCC) patients. It identified 81 apoptosis-related genes for molecular classification and revealed unique genomic alterations in Taiwanese HCC patients. Molecular classification using apoptosis-related genes could lead to new therapeutic approaches for HCC.
HEPATOLOGY INTERNATIONAL
(2023)
Article
Urology & Nephrology
Felix Feng, Branko Miladinovic, Ke Zhang, James J. Dignam, Daniel Wang, Margaret Yu, Howard Sandler
Summary: PSAR-based early endpoints, such as PSA nadir + 2 ng/ml and rising, PSA >5 ng/ml, or PSADT <6 mo +/- ADT initiation and NED, are associated with MFS, OS, and PCSS, and can identify clinically undetectable disease in patients with HRLPC.
Article
Biology
Subodh Kumar, Leutz Buon, Srikanth Talluri, Marco Roncador, Chengcheng Liao, Jiangning Zhao, Jialan Shi, Chandraditya Chakraborty, Gabriel Gonzalez, Yu-Tzu Tai, Rao Prabhala, Mehmet K. Samur, Nikhil C. Munshi, Masood A. Shammas
Summary: Subodh Kumar et al. identify a gene signature correlated with genomic instability and poor survival in esophageal adenocarcinoma (EAC), using a combination of integrative genomic analysis of patient data and laboratory validation in cell line models and mice. They find that inhibitors of some of the identified proteins, including TTK, could be used to reduce genomic evolution as well as inhibit growth of EAC cells.
COMMUNICATIONS BIOLOGY
(2021)
Article
Cell Biology
Lihui Jin, Zhenyuan Han, Zhongli Jiang, Jieru Lu, Yizhuo Wu, Bingqian Yan, Weibin Zhang, Xuedong Lin, Lvyan Jiang, Pengjun Zhao, Kun Sun
Summary: Complex VSD, combined with other cardiac or extracardiac malformations, is a major cause of perinatal morbidity and mortality. This study identified 93 low-frequency non-coding SNPs associated with complex VSD risk and recognized rs2279658 as a candidate cis-regulatory SNP through functional genomics analysis. The findings broaden our understanding of the pathogenesis of complex VSD.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Michel Bolla, Anouk Neven, Philippe Maingon, Christian Carrie, Ana Boladeras, Demetrios Andreopoulos, Antoine Engelen, Santhanam Sundar, Elzbieta M. van der Steen-Banasik, John Armstrong, Karine Peignaux-Casasnovas, Jihane Boustani, Fernanda G. Herrera, Bradley R. Pieters, Annerie Slot, Amit Bahl, Christopher D. Scrase, David Azria, Jan Jansa, Joe M. O'Sullivan, Alphonsus C. M. Van den Bergh, Laurence Collette
Summary: The study showed that 6 months of concurrent and adjuvant androgen suppression can significantly improve event-free survival and disease-free survival in intermediate-risk prostate cancer patients treated with irradiation at 74 or 78 Gy, but did not significantly impact overall survival and distant metastasis-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Hideya Yamazaki, Gen Suzuki, Koji Masui, Kei Yamada, Takashi Ueda, Takumi Shiraishi, Atsuko Fujihara, Takashi Kato, Yasutoshi Hashimoto, Haruumi Okabe
Summary: This study compared outcomes of patients with ultra-high iPSA levels to other high-risk patients after radiotherapy. The results showed that patients with ultra-high iPSA levels had worse biochemical disease-free survival and distant metastasis-free survival rates. The ultra-high iPSA group had higher rates of distant metastases, but similar rates of local failure and pelvic lymph node recurrence. Ultra-high iPSA levels could be considered as a candidate factor to identify high-risk patients who require intensified treatment.
Article
Oncology
Soumyajit Roy, Yilun Sun, Cristopher J. D. Wallis, Scott C. Morgan, Scott Grimes, Julia Malone, Amar U. Kishan, Dibya Mukherjee, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study developed and validated a multivariable prognostic model to predict overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC). The model includes 11 prognostic variables and showed high predictive accuracy on a testing set.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Richard L. Cantley, Xiaoming Wang, Zachery R. Reichert, Arul M. Chinnaiyan, Rahul Mannan, Xuhong Cao, Daniel E. Spratt, Ulka N. Vaishampayan, Joshi J. Alumkal, Todd M. Morgan, Ganesh Palapattu, Matthew S. Davenport, Liron Pantanowitz, Rohit Mehra
Summary: Fine needle aspiration (FNA) can be used to diagnose metastatic prostatic cancer (MPC) based on typical cytomorphologic and immunohistochemical (IHC) features, but the diagnosis may be complicated by atypical phenotypes induced by androgen deprivation therapy (ADT). Careful assessment of cytologic and biomarker features can provide important therapeutic and prognostic information in MPC.
CANCER CYTOPATHOLOGY
(2023)
Article
Oncology
Sagar A. Patel, Ting Martin Ma, Jessica K. Wong, Bradley J. Stish, Robert T. Dess, Avinash Pilar, Chandana Reddy, Trude B. Wedde, Wolfgang A. Lilleby, Ryan Fiano, Gregory S. Merrick, Richard G. Stock, D. Jeffrey Demanes, Brian J. Moran, Phuoc T. Tran, Daniel J. Krauss, Eyad I. Abu-Isa, Thomas M. Pisansky, C. Richard Choo, Daniel Y. Song, Stephen Greco, Curtiland Deville, Theodore L. DeWeese, Derya Tilki, Jay P. Ciezki, R. Jeffrey Karnes, Nicholas G. Nickols, Matthew B. Rettig, Felix Y. Feng, Alejandro Berlin, Jonathan D. Tward, Brian J. Davis, Robert E. Reiter, Paul C. Boutros, Tahmineh Romero, Eric M. Horwitz, Rahul D. Tendulkar, Michael L. Steinberg, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: For very-high-risk prostate cancer patients, the addition of brachytherapy to external beam radiation therapy with androgen deprivation therapy did not significantly improve outcomes compared to radiation therapy alone.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Pathology
Rahul Mannan, Xiaoming Wang, Pushpinder S. Bawa, Yuping Zhang, Stephanie L. Skala, Anya K. Chinnaiyan, Aniket Dagar, Lisha Wang, Sylvia B. Zelenka-Wang, Lisa M. McMurry, Nikita Daniel, Xuhong Cao, Ankur R. Sangoi, Sounak Gupta, Ulka N. Vaishampayan, Khaled S. Hafez, Todd M. Morgan, Daniel E. Spratt, Maria S. Tretiakova, Pedram Argani, Arul M. Chinnaiyan, Saravana M. Dhanasekaran, Rohit Mehra
Summary: LINC01187 is a novel biomarker that enhances the currently used KIT assay and facilitates microscopic analysis in routine surgical pathology practice.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
(2023)
Article
Oncology
Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach III, David Dearnaley, Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall, Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle, Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, Amar U. Kishan
Summary: The sequencing of androgen-deprivation therapy (ADT) and radiotherapy (RT) may affect the outcome of prostate cancer depending on the size of the RT field. A study found that the sequencing of ADT has a significant impact on clinical outcomes for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Randy A. Vince, Ralph Jiang, Merrick Bank, Jake Quarles, Milan Patel, Yilun Sun, Holly Hartman, Nicholas G. Zaorsky, Angela Jia, Jonathan Shoag, Robert T. Dess, Brandon A. Mahal, Kristian Stensland, Nicholas W. Eyrich, Mariana Seymore, Rebecca Takele, Todd M. Morgan, Matthew Schipper, Daniel E. Spratt
Summary: This meta-analysis demonstrates that the interaction between race and social determinants of health (SDOH) is associated with racial disparities in prostate cancer outcomes. Black patients have higher prostate cancer-specific mortality (PCSM) than White patients in studies with minimal accounting for SDOH, but lower PCSM in studies with greater accounting for SDOH. The findings underscore the importance of considering SDOH variables in research to promote health equity.
Correction
Health Care Sciences & Services
Andre J. Esteva, Jean Feng, Douwe van der Wal, Shih-Cheng Huang, Jeffry Simko, Sandy E. DeVries, Emmalyn Chen, Edward Schaeffer, Todd Morgan, Yilun Sun, Amirata A. Ghorbani, Nikhil Naik, Dhruv G. Nathawani, Richard D. Socher, Jeff L. Michalski, Mack R. Roach III, Thomas G. Pisansky, Jedidiah Monson, Farah A. Naz, James Wallace, Michelle M. Ferguson, Jean-Paul T. Bahary, James E. Zou, Matthew Lungren, Serena Y. Yeung, Ashley Ross, Howard M. Sandler, Phouc T. Tran, Daniel E. Spratt, Stephanie Pugh, Felix Y. Feng, Osama Mohamad
NPJ DIGITAL MEDICINE
(2023)
Article
Oncology
Clayton P. Smith, James A. Proudfoot, Paul C. Boutros, Robert E. Reiter, Luca Valle, Matthew B. Rettig, Nicholas G. Nickols, Felix Y. Feng, Paul L. Nguyen, Himanshu Nagar, Daniel E. Spratt, Gert Attard, Adam Weiner, Joanne B. Weidhaas, Jeremie Calais, T. Martin Ma, Elai Davicioni, Michael Xiang, Amar U. Kishan
Summary: PSMA PET has higher specificity and sensitivity than conventional imaging, and it can predict the risk of distant metastasis in high-risk and very high-risk prostate cancer patients. The risk of upstaging on PSMA PET is significantly correlated with the Decipher genetic score. Further studies are needed to explore the causal pathways between PSMA findings, Decipher scores, extraprostatic disease, and long-term clinical outcomes.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Meeting Abstract
Oncology
Ryan J. Rebernick, Liat Hammer, Matthew McFarlane, Thomas Westbrook, Munna Hazime, Tanya Hammoud, Pin-En Chiu, Yi-Mi Wu, Dan Robinson, Daniel Eidelberg Spratt, Ajjai S. Alva, William C. Jackson, Zachery R. Reichert, Arul Chinnaiyan, Joshi J. Alumkal, Robert T. Dess, Marcin Cieslik
Meeting Abstract
Urology & Nephrology
Udit Singhal, Ralph Jiang, Daniel E. Spratt, Matthew Schipper, Simpa S. Salami, Stephanie Daignault-Newton, Rodney Dunn, Thomas J. Maatman, Brian R. Lane, Frank N. Burks, Paul Rodriguez, Eduardo Kleer, Richard Sarle, Felix Y. Feng, Michael L. Cher, Robert T. Dess, Todd M. Morgan
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Zhiyu Qian, Edoardo Beatrici, Quoc-Dien Trinh, Adam S. Kibel, Stacy Loeb, Hari S. Iyer, Alexander P. Cole
Summary: As the climate crisis worsens, its impact on human health, including cancer pathogenesis and treatment, becomes increasingly evident. This study found a significant association between individuals' recognition of climate change as a personal health threat and their interest in cancer screening. These findings suggest a promising avenue for future research on the intersection of climate and cancer risk, and support the integration of environmental health literacy into public health interventions for cancer screening.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Meeting Abstract
Oncology
Liat Hammer, Ryan Rebernick, Matthew McFarlane, Thomas Westbrook, Munna Hazime, Tanya Hammoud, Pin-en Chiu, Owens Xavier, Yi-Mi Wu, Dan R. Robinson, Daniel Eidelberg Spratt, Ajjai Shivaram Alva, William C. Jackson, Zachery R. Reichert, Joshi J. Alumkal, Arul Chinnaiyan, Marcin Cieslik, Robert Timothy Dess
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Paul L. Nguyen, Marisa Kollmeier, Dana E. Rathkopf, Karen E. Hoffman, Amado J. Zurita, Daniel Eidelberg Spratt, Robert Timothy Dess, Stanley L. Liauw, Russell Zelig Szmulewitz, David Johnson Einstein, Glenn Bubley, James B. Yu, Yi An, Anthony C. Wong, Felix Y. Feng, Rana R. Mckay, Brent S. Rose, Kee-Young Shin, Adam S. Kibel, Mary-Ellen Taplin
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Irene Tsung, Stephen Hynes, Urvashi Mitbander Joshi, Krystal A. Morales, Robert Timothy Dess, William C. Jackson, Jeremy M. G. Taylor, Zachery R. Reichert
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Steven G. Allen, Chao Zhang, Shawn Malone, Soumyajit Roy, Robert T. Dess, William C. Jackson, Rohit Mehra, Corey Speers, Arul M. Chinnaiyan, Yilun Sun, Daniel E. Spratt
Summary: The sequencing of adjuvant androgen receptor-signaling inhibition (ARSI) after radiotherapy (RT) has been shown to have superior clinical outcomes compared to neoadjuvant/concurrent therapy. This study investigated the differential effects of ARSI sequencing on AR-signaling and DNA repair pathways in prostate cancer models. Results demonstrated that adjuvant ARSI following RT was more effective in inhibiting AR-signaling and cell growth, possibly through disruption of homologous recombination.
WORLD JOURNAL OF UROLOGY
(2023)